Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Walgreens announces clinical trial offerings 

By Brian Buntz | June 16, 2022

WalgreensThe drug store giant Walgreens (Nasdaq:WBA) has launched a clinical trial business aimed at optimizing patient experience, recruitment and clinical trial diversity.

Deerfield, Illinois–headquartered Walgreens will offer both in-person and virtual care clinical trial options.

In a press release, Walgreens underscored FDA’s push to improve racial and ethnic diversity in clinical studies. In 2020, three-fourths of clinical trial volunteers were white, and only 11% were Hispanic, while fewer than 10% were Black and Asian, according to FDA.

Walgreens intends to use pharmacy and patient-authorized clinical data to match diverse patient populations to clinical trials in an array of disease areas using race, gender, socioeconomic status and location data.

Walgreens also promises to help drug developers improve patient recruitment and enrollment in clinical trials. The company operates almost 9,000 stores. More than half of them are based in socially vulnerable areas.

“Through the launch of our clinical trials services, we can provide another offering for patients with complex or chronic conditions in their care journey, while helping sponsors advance treatment options for the diverse communities we serve,” said Ramita Tandon, chief clinical trials officer, Walgreens, in a statement. “This is yet another way we are building our next growth engine of consumer-centric healthcare solutions.”

The company also intends to help pharma and biotech companies use real-world evidence and informatics in clinical trials to inform drug development strategies, clinical trial design and execution.

In a related vein, Walgreens has created a COVID-19 index that has influenced national and local responses to the pandemic.

Walgreens has also established a smart care coordination service known as Pluto Health that integrates healthcare information from sources such as medical records, social determinants of health and insurance claims.

“Pluto Health was co-created within the healthcare community to make the provision of care achievable and more equitable for more people with better care coordination,” said Dr. Joy Bhosai, Pluto Health CEO, in a statement. “As a part of our primary goal to coordinate care and support patients on their terms, we are thrilled to play a part in making the latest medical advances more accessible. It’s time to accelerate healthcare access for all patients, from all walks of life, and from anywhere in the nation.”

To help lead the new business, Walgreens has made several new hires. Kendal Whitlock will serve as head of digital optimization, RWE clinical trials. John Campbell has joined as head of decentralized clinical trials. Liam Wood will serve as head of product, RWE clinical trials. Adam Samson will serve as the head of clinical delivery operations, RWE clinical trials.

In early afternoon trading, WBA shares fell 1.30% to $40.20, while the Nasdaq Composite index was down 3.83%


Filed Under: clinical trials, Drug Discovery
Tagged With: clinical trial, clinical trial diversity, Walgreens
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE